DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The "Ocular Hypertension: Drug Development Pipeline Study, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Ocular Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Ocular Hypertension industry.

Ocular Hypertension pipeline comprises of 27 drugs under development as of March 2018. Of these, 2 drugs are in Phase 1 and 13 drugs in phase 2 and 6 drugs in Phase 3. Further, 5 drugs remain in Pre-clinical stage. One drug is in pre-registration stage.

20 companies are developing the pipeline for Ocular Hypertension. Of this, Santen Pharmaceutical Co Ltd and NicOx SA have largest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Prostaglandin E EP2 receptor agonist.

Key Topics Covered:

1 Figures & Tables

2 Executive Summary

2.1 Disease Overview

2.2 Pipeline Snapshot

2.3 Pipeline Drugs By Phase

2.4 Pipeline Drugs By Company

2.5 Pipeline Drugs By Mechanism Of Action

3 Ocular Hypertension- Company Wise Pipeline Analysis

3.1 Aerie Pharmaceuticals, Inc

3.2 Alcon Laboratories Inc

3.3 Allergan Plc

3.4 Can-Fite Biopharma Ltd

3.5 D. Western Therapeutics Institute Inc

3.6 Envisia Therapeutics Inc

3.7 F. Hoffmann-La Roche Ltd

3.8 Ironwood Pharmaceuticals Inc

3.9 Laboratorios Sophia S.A. De C.V

3.10 Mati Therapeutics Inc

3.11 Neurim Pharmaceuticals Ltd

3.12 Nicox Sa

3.13 Ocular Therapeutix Inc

3.14 Peregrine Ophthalmic

3.15 Santen Pharmaceutical Co Ltd

3.16 Senju Pharmaceutical Co.,Ltd

3.17 Shire Plc

3.18 Sylentis Sau

3.19 Taejoon Pharmaceutical Co., Ltd.

3.20 Visci Ltd.

4 Ocular Hypertension Drug Snapshots

4.1 Roclatan

4.2 Mgv354

4.3 Bimatoprost Ocular Insert

4.4 Cf 101

4.5 Wp-1303

4.6 Env515

4.7 Rg 7945

4.8 Iwp 953

4.9 Soph067

4.10 Pro-122

4.11 Piromelatine

4.12 Ncx 470

4.13 Ncx 667

4.14 Ncx 1653

4.15 Otx-Tp

4.16 Otx-Tic

4.17 De-117

4.18 De 126

4.19 De-130A

4.20 Y-39983

4.21 Sjp 0135

4.22 Shp 639

4.23 Bamosiran

4.24 Latanoprost-Ppds

4.25 Vs 101

4.26 Liposomal Latanoprost

4.27 Tjo 002

5 Recent Developments In Ocular Hypertension Pipeline

5.1 FDA Approves Latanoprostene Bunod Ophthalmic Solution 0.024% - November 2017

5.2 Daily Use Of Steroid Drops Increases Risk For Ocular Hypertension - July 2017

5.3 Nicox Provides Clinical And Regulatory Update For Ncx 470 For Iop Lowering- January 2017

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/59kfcp/ocular?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612006412/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Transdermal and Transmucosal Drug Delivery,Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 03:24 PM/DISC: 06/12/2018 03:24 PM

http://www.businesswire.com/news/home/20180612006412/en